Pharmaceuticals companies continue to fall foul of the FCPA and other anti-bribery laws, with a number of 2016 cases suggesting a vulnerability around marketing practices especially in the Asia-Pacific region. Why does a sector that is way ahead of the compliance game in so many ways keep getting caught out by anti-bribery laws?
Entries in AstraZeneca (11)
The Securities and Exchange Commission Tuesday charged U.K.-based pharma AstraZeneca PLC with violating the books and records and internal controls provisions of the Foreign Corrupt Practices Act when wholly-owned subsidiaries in China and Russia made illegal payments to boost drug sales.
Pharma AstraZeneca LP agreed to pay $7.9 million to settle allegations that it violated the False Claims Act by paying kickbacks to sell its drugs, the DOJ said Wednesday.
Pharmas have told their sales teams to halt all activity in China to avoid being caught in the nationwide “enforcement storm,” according to the Guangdong-based Yangcheng Evening News.
China state media reported Saturday that French drugmaker Sanofi SA is under investigation for allegedly bribing doctors to increase sales.
U.K.-based pharma AstraZeneca said its office in Belgrade, Serbia was served with a criminal indictment 'relating to allegations that local employees . . . made allegedly improper payments to physicians at the Institute of Oncology and Radiology of Serbia.'